Core Viewpoint - The capital market is undergoing a quiet transformation from cash dividends to tangible rewards for shareholders, with over 30 A-share companies participating in physical rewards, marking a 45% increase compared to the previous year [1]. Group 1: Physical Rewards "Trio" - Brand value is being tangibly integrated, with companies like Wufangzhai using QR codes on products to enhance brand engagement, resulting in a 230% average increase in social media exposure for participating companies [5]. - Companies are transforming shareholders into "product experience officers," with Tianyu Bio collecting over 2,000 feedbacks to optimize products, leading to a 40% increase in pre-sale volumes for improved designs [6]. - Strategic designs like Sichuan Changhong's "discount coupons" create a consumption-points-rights loop, increasing customer lifetime value by 65% and tripling repurchase rates compared to conventional channels [7]. Group 2: Innovation Behind "Offensive and Defensive Strategies" - Industry-specific strategies are being employed, such as Wufangzhai combining its products with cultural elements and Stone Technology providing cleaning solutions with their products [8]. - Leading companies are reducing reward costs through supply chain collaboration, with companies like Beiliang reducing marginal costs by 42% for exclusive products [9]. - Compliance risks are highlighted, with examples of companies facing scrutiny for non-compliant rewards, emphasizing the need for adherence to investor relations management guidelines [9]. Group 3: Future Competition - Digital empowerment is enhancing experiences, as seen with Bona Film's NFT movie tickets allowing shareholders to redeem physical tickets and merchandise [11]. - The C2M revolution is emerging, with companies like Dong'e Ejiao customizing products based on shareholder health data, achieving a 38% customer conversion rate [16]. - ESG values are being integrated into shareholder rewards, with companies like CATL embedding carbon credits into gifts, representing a shift in shareholder value perception [19]. Group 4: Critical Reflections - The physical reward trend faces challenges, including value disputes over inflated product prices and fairness concerns for minority shareholders [21]. - A suggested three-dimensional evaluation system includes ensuring the physical value does not exceed 5% of annual net profit, providing dual channels for participation, and maintaining transparency in reporting [21]. - The shift from financial rewards to future-oriented value creation is redefining the rules of engagement in the capital market, emphasizing the importance of product, operational, and innovative capabilities [21].

Core Insights - The aging population in China is leading to an increase in cervical spondylosis cases, particularly among those aged 60 and above, while younger demographics are also increasingly affected due to modern lifestyle habits [1][7] - The market for cervical spondylosis medication is projected to reach 13 billion yuan in 2024, reflecting a year-on-year growth of 16.1% [1][7] - The industry is supported by government reforms aimed at expanding healthcare coverage and improving the pharmaceutical sector [1][5] Industry Overview - Cervical spondylosis is caused by degenerative changes in the cervical spine, leading to various types such as nerve root type, spinal cord type, sympathetic type, and vertebral artery type [3] - The treatment typically begins with non-surgical methods, including physical therapy, exercise therapy, and medication [4] Market Dynamics - The cervical spondylosis medication market is expanding due to an increase in patient numbers, with over 200 million patients reported in 2024, and more than 40% of them being under 30 years old [6][7] - The demand for cervical spondylosis medications is rising as healthcare reforms enhance public access to medical services [1][7] Competitive Landscape - The market is characterized by intense competition among domestic pharmaceutical companies, with some firms focusing on product development and brand building to capture market share [8][9] - Key players in the industry include Yunnan Baiyao Group, Renhe Pharmaceutical, and Henan Lingrui Pharmaceutical, among others [9] Industry Trends - The product structure is evolving, with non-steroidal anti-inflammatory drugs (NSAIDs) remaining dominant, while new drug types like targeted therapies and biological agents are emerging [10] - Companies are increasingly looking to expand into international markets, enhancing brand presence and product quality to compete globally [11][12] - Sales channels are diversifying, with a growing emphasis on online sales and the establishment of specialized health sections in pharmacies [13]

Core Viewpoint - Xinhua Group plans to issue exchangeable bonds backed by its shares in Yunnan Baiyao, with a total issuance scale of up to 2 billion RMB [2][4]. Group 1: Exchangeable Bonds Issuance - Xinhua Group intends to issue exchangeable bonds using part of its A-share holdings in Yunnan Baiyao as collateral [2]. - The issuance has received approval from the Shenzhen Stock Exchange, confirming it meets the listing conditions [2]. - The bonds will be managed by Guosen Securities as the nominal holder, with specific accounts set up for the transaction [2]. Group 2: Bond Details - The total issuance scale of the bonds is capped at 2 billion RMB [4]. - The bonds have a coupon rate of 0.1% and a maturity period of 3 years [4]. - The initial conversion price is set at 71.66 RMB per share, with the conversion period starting from April 23, 2026, to October 20, 2028 [4][3].

Core Viewpoint - Yunnan Baiyao Group Co., Ltd. has decided to cancel its supervisory board and amend its articles of association, which will be submitted for approval at the upcoming extraordinary general meeting of shareholders [1][3]. Group 1: Board Meeting Resolutions - The board meeting held on October 24, 2025, approved the cancellation of the supervisory board and the revision of the articles of association in accordance with relevant laws and regulations [1][41]. - The board also approved the revision of the "Rules of Procedure for Shareholders' Meetings," which will now be renamed "Rules of Procedure for Shareholder Meetings" [5]. - The board approved the revision of the "Rules of Procedure for Board Meetings" [8]. - The board approved the revision of the "Rules of Procedure for Office Meetings," which will now be renamed "Rules of Procedure for the President's Office Meetings" [11]. - The board approved the revision of the "Implementation Rules of the Board Strategic Committee," which will now be renamed "Work Regulations of the Board Strategic Committee" [13]. - The board approved the revision of the "Implementation Rules of the Board Audit Committee," which will now be renamed "Work Regulations of the Board Audit Committee" [15]. - The board approved the revision of the "Implementation Rules of the Board Compensation and Assessment Committee," which will now be renamed "Work Regulations of the Board Compensation and Assessment Committee" [17]. - The board approved the revision of the "Implementation Rules of the Board Nomination Committee," which will now be renamed "Work Regulations of the Board Nomination Committee" [19]. - The board nominated candidates for the 11th Board of Directors, which will be submitted for election at the upcoming shareholders' meeting [21][23]. - The board also nominated candidates for independent directors for the 11th Board of Directors, which will also be submitted for election [23][24]. Group 2: Upcoming Shareholder Meeting - The company will hold the 2025 Second Extraordinary General Meeting of Shareholders on November 10, 2025, to review the resolutions passed by the board [27][45]. - The meeting will be conducted in a hybrid format, combining on-site voting and online voting [47]. - Shareholders must register to attend the meeting, and the registration period is from November 4, 2025 [53].

Group 1 - Yunnan Baiyao held its sixth board meeting of the tenth session on October 24, 2025, to review the proposal for amending the "Board Meeting Rules" [1] - For the first half of 2025, Yunnan Baiyao's revenue composition was as follows: commercial sales accounted for 59.78%, industrial sales for 40.01%, other businesses for 0.1%, technical development services for 0.08%, and hospitality and catering for 0.03% [1] - As of the report date, Yunnan Baiyao's market capitalization was 100.6 billion yuan [1] Group 2 - A well-known brand spent 170 million yuan to acquire 2,000 shares of a target company with a registered capital of only 10,000 Hong Kong dollars, which has not yet commenced operations, raising questions about the necessity of the acquisition [1]

云南白药集团股份有限公司 董事会审计委员会工作规程 （2025 年 10 月修订） 第一章 总 则 第一条 为强化云南白药集团股份有限公司（以下简称"公司"）董事会决 策功能，规范公司董事会审计委员会的运作，确保董事会对经营管理层的有效监 督，充分发挥审计在风险防控中的作用，根据《中华人民共和国公司法》《上市 公司治理准则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》《云南白药集团股份有限公司公司章程》（以下简称《公司章程》） 等相关规定，公司董事会设立审计委员会，并制定本工作规程。 第二条 审计委员会是董事会按照《公司章程》设立的专门工作机构，行使 《公司法》规定的监事会的职权，负责监督及评估公司外部、内部审计工作，监 督及评估公司的内部控制并审核公司的财务信息及其披露。 第三条 本工作规程所称董事、高级管理人员均与《公司章程》规定一致。 第二章 人员组成 第四条 董事会审计委员会委员由五名董事组成，其中独立董事三名，不在 公司担任高级管理人员的董事两名，由独立董事中会计专业人士担任召集人。 会计专业人士应具备较丰富的会计专业知识和经验，并至少符合下列条件之 一：（1）具有注册 ...

云南白药集团股份有限公司 总裁办公会议事规则 （2025 年 10 月修订） 第一章 总则 第一条 为加强集体领导，保证云南白药集团股份有限公司（以 下简称"集团"或"公司"）总裁办公会议事决策的科学化、制度化 和规范化，切实提高总裁办公会议事决策水平和能力，根据《公司章 程》《云南白药集团股份有限公司首席执行官工作细则》、集团董事 会对总裁办公会的授权，结合公司实际，制定本规则。 第二条 总裁办公会坚持"各抒己见、充分讨论，发扬民主、从 善如流，凝聚智慧、集中决策"的原则，支持总裁（首席执行官）科 学有效地实施决策。 第三条 总裁办公会是总裁（首席执行官）对经营管理等工作实 施有效领导的组织形式，总裁办公会最终的决策由总裁（首席执行官） 裁决并为之负责。 第二章 会议召集 第四条 总裁办公会由总裁（首席执行官）召集和主持，总裁（首 席执行官）不能履行职责时，可以委托一名高级副总裁代为召集和主 持。 第三章 参会人员 - 1 - 第五条 参会人员范围为：经营层高级管理人员、行政管理部门 负责人、议题或报告事项拟制单位负责人（只参加该议题或报告事项 的讨论或报告环节）及总裁（首席执行官）认为需参会的其他人员等。 ...

云南白药集团股份有限公司 公司章程 （2025 年 10 月修订） 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 公司党委 第六章 董事和董事会 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第七章 高级管理人员 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知与公告 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十一章 修改章程 第十二章 附则 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）、《中国共产党章程》和 ...

云南白药集团股份有限公司 董事会战略委员会工作规程 （2025 年修订） 第一章 总 则 第一条 为适应云南白药集团股份有限公司（以下简称"公司"）战略发展 需要，增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加强决策 科学性，提高重大投资决策的效益和决策的质量，完善公司治理结构，根据《中 华人民共和国公司法》《上市公司治理准则》《公司章程》《董事会议事规则》 等相关规定，公司董事会设立战略委员会，并制定本工作规程。 第二条 战略委员会是董事会按照《公司章程》设立的专门工作机构，主要 负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，则该委员自动失去委员资格，并由董事会 根据上述第三至第五条规定补足委员人数。 第三章 职责权限 第七条 战略委员会对董事会负责，依据董事会的要求履行以下职责： （一）对公司的发展战略或规划进行研究并提出意见或建议； （二）对《公司章程》、《董事会议事规则》中规定需提交董事会审议的对 外投资（包含但不限于股权投资、债权投资、证券投资、衍生品投资 ...

云南白药集团股份有限公司 董事会议事规则 （2025 年 10 月修订） 第一章 总 则 第一条 为规范云南白药集团股份有限公司（以下简称"公司" 或"本公司"）董事会的行为，确保董事会高效运作和科学决策，根 据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》和《云南白药集团股份有限公司公司章程》（以下简 称《公司章程》）的规定，制定本规则。 第二条 董事会是股东会的执行机构，在股东会闭会期间负责公 司重大经营决策，对股东会负责。 第三条 董事会秘书负责董事会会议的组织和准备工作，包括安 排会议日程、准备会议文件、组织会议召开、负责会议记录、起草会 议决议、纪要等。 第二章 董事会的组成与职权 第四条 董事会由十二名董事组成，其中独立董事四名，职工代 表董事一名。董事会设董事长一名，可以设副董事长一名。董事长和 副董事长由董事会以全体董事的过半数选举产生。 第五条 公司董事会设立审计委员会，并根据需要设立战略委员 会、提名委员会、薪酬与考核委员会等相关专门委员会。专门委员会 对董事会负责，依照《公司章程》和董事会授权履行职责，提案应当 提交董事会审议决定。专门委员会成员全部由董事组成 ...